Insights

Home » Insights » INTERCEPT Blood System for massively transfused patients

Categories

INTERCEPT Blood System for massively transfused patients

06/07/2018

New publication confirms clinical efficiency and patient safety of INTERCEPT™ Blood System for platelets

Large Austrian Medical Centre publishes study results on component utilization and patient safety after adoption of platelet pathogen inactivation.

The Medical University Hospital in Innsbruck has evaluated the influence of the INTERCEPT™ Blood System for platelets on component utilization and patient safety. The effectiveness of conventional vs. INTERCEPT™-treated platelets was analyzed during two 21-month periods before and after implementation of pathogen inactivation.

Results of the study were published recently in Vox Sanguinis - The Internal Journal of Transfusion Medicine.

Access the abstract and open access article
← 2 million Swiss francs to develop a whole blood PI system in Africa
The economics of Double Dose Buffy Coat Platelets →

Ask an Expert

Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.

Ask an Expert

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0